首页> 外文期刊>Infection and immunity >Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine
【24h】

Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine

机译:白喉毒素的交叉反应材料CRM197的经皮免疫提高了经吸附的白喉类毒素疫苗肠胃外免疫小鼠的功能性抗体水平

获取原文
       

摘要

Transcutaneous immunization (TCI) capitalizes on the accessibility and immunocompetence of the skin, elicits protective immunity, simplifies vaccine delivery, and may be particularly advantageous when frequent boosting is required. In this study we examined the potential of TCI to boost preexisting immune responses to diphtheria in mice. The cross-reacting material (CRM197) of diphtheria toxin was used as the boosting antigen and was administered alone or together with either one of two commonly used mucosal adjuvants, cholera toxin (CT) and a partially detoxified mutant of heat-labile enterotoxin of Escherichia coli (LTR72). We report that TCI with CRM197 significantly boosted preexisting immune responses elicited after parenteral priming with aluminum hydroxide-adsorbed diphtheria toxoid (DTxd) vaccine. In the presence of LTR72 as an adjuvant, toxin-neutralizing antibody titers were significantly higher than those elicited by CRM197 alone and were comparable to the functional antibody levels induced after parenteral booster immunization with the adsorbed DTxd vaccine. Time course study showed that high levels of toxin-neutralizing antibodies persisted for at least 14 weeks after the transcutaneous boost. In addition, TCI resulted in a vigorous antigen-specific proliferative response in all groups of mice boosted with the CRM197 protein. These findings highlight the promising prospect of using booster administrations of CRM197 via the transcutaneous route to establish good herd immunity against diphtheria.
机译:透皮免疫(TCI)利用了皮肤的可及性和免疫能力,引发了保护性免疫,简化了疫苗的运送,当需要频繁加强免疫时尤其有利。在这项研究中,我们研究了TCI增强小鼠白喉现有免疫反应的潜力。白喉毒素的交叉反应物质(CRM 197 )用作增强抗原,可以单独使用,也可以与两种常用的粘膜佐剂霍乱毒素(CT)和部分排毒的一种一起给药大肠杆菌热不稳定性肠毒素(LTR72)的突变体。我们报告说,与CRM 197 的TCI显着增强了用氢氧化铝吸附的白喉类毒素(DTxd)疫苗进行肠胃外启动后引起的预先存在的免疫反应。在存在LTR72作为佐剂的情况下,毒素中和抗体的滴度明显高于单独使用CRM 197 引起的滴度,并且与吸附的DTxd疫苗肠胃外加强免疫后诱导的功能抗体水平相当。时程研究表明,经皮加强免疫后,高水平的毒素中和抗体持续至少14周。此外,TCI在用CRM 197 蛋白增强的所有小鼠组中均引起强烈的抗原特异性增殖反应。这些发现凸显了通过经皮途径加强使用CRM 197 来建立良好的抗白喉牛群免疫的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号